Up to 60–70% of NHL patients and 90–95% of B-ALL patients have been found to respond to anti-CD19 CAR T-cell therapy, while the response rate is lower in CLL patients (50–70%) [12,13,14,15,16,17]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.